Skip to main content

Table 2 Patients characteristics

From: Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

Number of patients

12

Age

Median

 50–74

64

PS

 0

4 (33%)

 1

8 (67%)

Receptor status

 ER+

12 (100%)

 HER2+

3 (25%)

Adjuvant therapy

 chemotherapy

7 (58%)

 endocrine

7 (58%)

 Primary disseminated disease

1 (8%)

Prior chemo regimens for metastatic disease

 2

2 (17%)

 3

6 (50%)

 4

4 (33%)

Metastatic sites

 Lymph nodes

5 (42%)

 Bone

10 (83%)

 Lung

6 (50%)

 Pleura

5 (42%)

 Liver

8 (67%)

 Skin

1 (8%)

 Ipsilateral breast

2 (17%)